Drugs / MSC-exos-P1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06919380 | Apr 2025 → Dec 2026 expected | anti-MDA5 dermatomyositis, interstitial lung disease | Li Shiyue | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC-exos-P1 | “nebulized mesenchymal stem cell-derived exosomes (MSC-exos-P1)” NCT06919380 ↗ |
| Modality | Other / unclassified | “mesenchymal stem cell-derived exosomes (MSC-exos-P1)” NCT06919380 ↗ |
| Route | Inhaled | “daily nebulized MSC-exos-P1” NCT06919380 ↗ |